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A B S T R A C T
Loss of dopaminergic nigrostriatal neurons and fibrillary α-synuclein (α-syn) aggregation in Lewy bodies (LB)
characterize Parkinson's disease (PD). We recently found that Synapsin III (Syn III), a phosphoprotein regulating
dopamine (DA) release with α-syn, is another key component of LB fibrils in the brain of PD patients and acts as a
crucial mediator of α-syn aggregation and toxicity.
Methylphenidate (MPH), a monoamine reuptake inhibitor (MRI) efficiently counteracting freezing of gait in
advanced PD patients, can bind α-syn and controls α-syn-mediated DA overflow and presynaptic compart-
mentalization. Interestingly, MPH results also efficient for the treatment of attention deficits and hyperactivity
disorder (ADHD), a neurodevelopmental psychiatric syndrome associated with Syn III and α-syn polymorphisms
and constituting a risk factor for the development of LB disorders.
Here, we studied α-syn/Syn III co-deposition and longitudinal changes of α-syn, Syn III and DA transporter
(DAT) striatal levels in nigrostriatal neurons of a PD model, the human C-terminally truncated (1−120) α-syn
transgenic (SYN120 tg) mouse, in comparison with C57BL/6J wild type (wt) and C57BL/6JOlaHsd α-syn null
littermates. Then, we analyzed the locomotor response of these animals to an acute administration of MPH (d-
threo) and other MRIs: cocaine, that we previously found to stimulate Syn III-reliant DA release in the absence of
α-syn, or the selective DAT blocker GBR-12935, along aging. Finally, we assessed whether these drugs modulate
α-syn/Syn III interaction by fluorescence resonance energy transfer (FRET) and performed in silico studies en-
gendering a heuristic model of the α-syn conformations stabilized upon MPH binding.
We found that only MPH was able to over-stimulate a Syn III-dependent/DAT-independent locomotor activity in the
aged SYN120 tg mice showing α-syn/Syn III co-aggregates. MPH enhanced full length (fl) α-syn/Syn III and even more
(1–120) α-syn/Syn III interaction in cells exhibiting α-syn/Syn III inclusions. Moreover, in silico studies confirmed that
MPH may reduce α-syn fibrillation by stabilizing a protein conformation with increased lipid binding predisposition.
Our observations indicate that the motor-stimulating effect of MPH can be positively fostered in the presence of α-
syn/Syn III co-aggregation. This evidence holds significant implications for PD and ADHD therapeutic management.
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1. Introduction
Synapsin III (Syn III) is a synaptic phosphoprotein negatively reg-
ulating striatal dopamine (DA) release by cooperating with α-synuclein
(α-syn) (Hosaka and Sudhof, 1998; Kile et al., 2010; Zaltieri et al.,
2015). We recently described that in Parkinson's disease (PD), the most
common neurodegenerative movement disorder, characterized by
progressive loss of dopaminergic neurons of the substantia nigra, Syn III
associates with α-syn to compose the insoluble fibrils forming Lewy
Bodies (LB) (Longhena et al., 2018; Spillantini et al., 1997). Aggrega-
tion and deposition of α-syn at synaptic sites are considered as the
primum movens for the derangement of dopaminergic neurons in PD
(Bellucci et al., 2016). Our recent findings support that, besides com-
posing α-syn insoluble fibrils, Syn III acts as a crucial mediator of α-syn
aggregation and toxicity. Indeed, Syn III knock out (ko) mice do not
develop α-syn insoluble aggregates and the related degeneration of
dopaminergic nigrostriatal neurons prompted by the adeno-associated
virus (AAV)-induced overexpression of human wild type (wt) α-syn
(Faustini et al., 2018).
Syn III regulates DA release and is the only synapsin co-localizing
with vesicular monoamine transporter 2 (VMAT2) in the striatum
(Bogen et al., 2006; Faustini et al., 2018). Our previous studies in-
dicating that Syn III is up-regulated in the absence of α-syn in me-
sencephalic dopaminergic neurons subjected to α-syn gene silencing, or
produced from α-syn null mice (C57BL/6JOlaHsd), support the ex-
istence of a crucial interplay between Syn III and α-syn (Zaltieri et al.,
2015). The compensatory increase of Syn III observed in mice lacking
α-syn mediates a paradoxical over-response to the administration of the
monoamine reuptake inhibitor (MRI) cocaine, which can stimulate sy-
napsin-dependent DA release (Venton et al., 2006). Contrariwise, the
selective DA transporter (DAT) blocker GBR-12935 does not exert the
same effect (Zaltieri et al., 2015).
Twelve-month-old transgenic mice, overexpressing C-terminally trun-
cated (1–120) α-syn (SYN120 tg) under the guidance of rat tyrosine hy-
droxylase (TH) promoter, on the mouse C57BL/6JOlaHsd α-syn null
background, show a marked co-accumulation of α-syn and Syn III in the
striatum (Zaltieri et al., 2015), similarly to PD patients (Longhena et al.,
2018). These mice progressively develop α-syn insoluble aggregates in
dopaminergic nigrostriatal neurons from 2 months of age. At 12 months of
age, they exhibit reduced basal and K+-stimulated striatal DA release as-
sociated with redistribution of soluble NSF attachment protein receptor
(SNARE) proteins and DAT, without a frank dopaminergic cell loss
(Bellucci et al., 2011; Garcia-Reitbock et al., 2010; Tofaris et al., 2006).
Amphetamine-induced motor abnormalities are also detected at 18 months
of age (Tofaris et al., 2006). Thus, this transgenic mouse line constitutes a
progressive model of PD, recapitulating the earliest α-syn-related synaptic
derangement of dopaminergic neurons that may initiate neuronal loss
(Garcia-Reitbock et al., 2010). This is in line with evidence supporting the
relevance of truncated α-syn in the early pathogenic steps leading to LB
formation (Prasad et al., 2012). Indeed, the core of LB is enriched in C-
terminally truncated α-syn (Prasad et al., 2012), which assembles into fi-
laments and forms inclusions much more readily than full length (fl), wt or
mutated protein (Crowther et al., 1998; Fares et al., 2016).
Methylphenidate (MPH), a MRI currently used for the treatment of
attention deficits and hyperactivity disorder (ADHD) (Huss et al.,
2017), that can be associated with Syn III or α-syn polymorphisms
(Basay et al., 2016; Gerlach et al., 2019; Kenar et al., 2013), has been
found to efficiently counteract freezing of gait in advanced PD (Delval
et al., 2015; Devos et al., 2007; Moreau et al., 2012; Nikolai Gil D.
Reyes, 2018; Pollak et al., 2007). Notably, MPH displays α-syn binding
ability and results able to stimulate α-syn-mediated DA neuro-
transmission (Chadchankar et al., 2012; Kile et al., 2010; Venton et al.,
2006), supporting that α-syn/Syn III interplay may influence the effect
of this drug. The aim of this study was to assess whether and how the
formation of α-syn/Syn III co-aggregates in SYN120 tg mice may affect
the locomotor response to MPH.
To this purpose, we first characterized Syn III accumulation within
thioflavin S/α-syn-positive inclusions in the nigrostriatal neurons of
SYN120 tg mice. Then, we evaluated how α-syn expression and ag-
gregation may affect Syn III and DAT levels in the striatum and studied in
parallel MPH-, cocaine- and GBR-12935-stimulated locomotor activity in
C57BL/6J, C57BL/6JOlaHsd and SYN120 tg mice along aging. Finally,
we investigated whether these drugs can affect α-syn/Syn III interaction
in cells displaying α-syn/Syn III co-aggregates and performed in silico
studies to confirm stable binding between MPH and either human fl or C-
terminally truncated α-syn. Our results support that the pathological α-
syn/Syn III co-deposition produces a synaptic microenvironment en-
gendering the formation of specific α-syn conformational variants
boosting a Syn III-dependent motor response to MPH.
2. Material and methods
2.1. Animals
C57BL/6J wt mice (Charles River, Wilmington, MA), C57BL/
6JOlaHsd carrying a spontaneous deletion of α-syn gene (Harlan Olac,
Bicester, UK) and SYN120 tg mice (Tofaris et al., 2006) were used in
this study at 3, 8, 12, 16 months of age. Syn III ko mice were analyzed at
12 months of age. Mice were bred in our animal house facility at the
Department of Molecular and Translational Medicine of University of
Brescia. Animals were maintained under a 12 h light–dark cycle at a
room temperature (rt) of 22 °C and had ad libitum food and water. All
experiments were made in accordance to Directive 2010/63/EU of the
European Parliament and of the Council of 22 September 2010 on the
protection of animals used. All experimental and surgical procedures
conformed to the National Research Guide for the Care and Use of
Laboratory Animals were approved by the Animal Research Committees
of the University of Brescia (Protocol Permit 719/2015-PR). All
achievements were made to minimize animal suffering and to reduce
the number of animals used.
2.2. Animal surgery
The plasmids for the production of short hairpin (sh) AAV serotype
2/6 driven by the U6 promoter to silence the Syn III were acquired by
Vector biolabs (Malvern, PA, USA).
Twelve-month-old SYN120 tg mice were bilaterally injected in the
substantia nigra with either an AAV transducing an shRNA for Syn III gene
silencing (AAV-shSyn III) or a scramble shRNA (AAV-shScramble) at a
concentration of 1012 genome copies/ml. Briefly, animals were anesthe-
tized and placed in a stereotactic head frame (Stoelting, IL, USA). After
making a midline incision of the scalp, a hole was drilled in the appropriate
location for the substantia nigra at the left and right site of the skull. Two
microliters of AAV-shSyn III or AAV-shScramble were injected at a rate of
0.2 μl/min with a 33-gauge needle on a 10 μl Hamilton syringe at the
following coordinates: antero-posterior – 3.70; medio-lateral + and – 1.50;
dorsal-ventral – 3.9 relative to Bregma (Paxinos, 2012). The needle was left
in place for additional 5 min before being slowly retracted from the brain.
The locomotor activity of the AAV-shSynIII- and AAV-shScramble-in-
oculated mice was evaluated 4 months after the AAV injections.
2.3. Triple immunofluorescence staining
Twelve months old C57BL/6J, C57BL/6JOlaHsd and SYN120 tg
mice were anesthetized with chloral hydrate 400 mg/kg intraperitoneal
(i.p.) (Sigma-Aldrich, St. Louis, MO, USA) and transcardially perfused
with ice-cold Immunofix (4% PFA, Bio-optica, Milan, Italy). Brains were
post-fixed for 4 h in Immunofix and conserved in 18% sucrose (Sigma-
Aldrich) in PBS 0.1 M. The brains were then cut in 25 μm coronal
sections with a cryostat and conserved in 60% glycerol.
After permeabilization in PBS 0.1 M supplemented with 20% me-
thanol and 0.3% Triton X-100, free floating slices were incubated for
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5 h at rt. in strong blocking solution (10% Normal Goat Serum (NGS),
3% Bovine Serum Albumin (BSA), 0.05% NaN3, 0.3% Triton-X100 in
PBS 0.1 M) and then with the primary antibody in blocking solution
overnight at 4 °C. The following day, slices were washed with 0.3%
Triton-X100 PBS 0.1 M and incubated with the fluorochrome-con-
jugated secondary antibody in 0.3% Triton-X100 PBS 0.1 M plus 1 mg/
ml BSA for 1 h at rt. After three washes in 0.3% Triton X-100 PBS, slices
were incubated for 2 h at rt with the second primary antibody prepared
in blocking solution, followed by incubation for 1 h at rt with the op-
timal fluorochrome-conjugated secondary antibody. The sections un-
dergoing triple immunolabeling were further subjected to incubation
with a third primary antibody for 2 h at rt followed by incubation for
1 h with the fluorochrome-conjugated secondary antibody. Finally, cell
nuclei were counterstained with TO-PRO®-3 Iodide (To Pro, Thermo
Fisher Scientific, Waltham, USA), a carbocyanine monomer nucleic acid
stain with far-red fluorescence, and the slices were mounted onto su-
perfrost slides using Vectashield mounting medium for fluorescence
(Vector Laboratories, Burlingame, CA).
2.4. Thioflavin S staining
For thioflavin S staining, mouse brain sections were incubated with
0.05% of Thioflavin S (Sigma-Aldrich) in ethanol 50%, washed three
times for 10 s in 80% ethanol as previously described (Faustini et al.,
2018) and then blocked for subsequent immunostaining with the an-
tibody against Syn III. Cell nuclei were counterstained with Hoechst
33258 dye, mounted and analyzed by using a confocal microscope.
2.5. In situ Proximity Ligation Assay (PLA) studies
The in situ PLA studies on mice tissues were performed by using the
Duolink assay kit (O-LINK Bioscience, Upsalla, Sweden) with a protocol
adapted from the manufacturer's instruction, as previously described
(Faustini et al., 2018). Briefly, tissues were incubated with blocking
solution for 1 h and then with the primary antibodies recognizing Syn
III and α-syn at 1:500 dilution overnight at 4 °C. On the following day,
samples were incubated with PLA probe solution for 1 h at 37 °C and
with the ligation solution for 30 min at 37 °C, then with the amplifi-
cation solution at 37 °C for 100 min. Finally, tissues were washed and
subjected to another staining with TH antibody for 2 h at rt and probed
with the secondary antibody. Cell nuclei were then counterstained with
Hoechst 33258 dye and sections were mounted on slides and analyzed
by using a confocal microscope.
2.6. Confocal microscopy
Slides were observed by LSM 880 Zeiss confocal laser microscope
(Carl Zeiss S.p.A., Milan, Italy) with the following laser sets: λ = 405/
488/543/633 nm for quadruple TH/α-syn/Syn III/To Pro staining,
488/543/405 for triple TH/PLA/Hoechst or 543/430/405 for Syn III/
Thioflavin S/Hoechst staining. The height of sections scanning was
1 μm. Images (512 × 512 pixels) were then reconstructed using ZEISS
ZEN Imaging Software (Carl Zeiss S.p.A.).
2.7. Image analysis of Syn III-immunopositive area in the substantia nigra
For the quantification of Syn III immunoreactivity in the substantia
nigra the acquisition parameters during confocal imaging were main-
tained constant for all the images acquired to perform the analysis.
Brains from 3 to 4 mice (10 sections from each mouse, two every
150 μm) were analyzed by examining the whole area of the substantia
nigra within a virtual standard grid composed of 8 fields. The total Syn
III-positive area within the grid was estimated by using the FIJI soft-
ware. The mean of Syn III-positive area per section was calculated by
averaging the values of the 10 grids analyzed for each animal in the
different experimental groups. Values were then expressed as %
changes vs C57BL/6J mice.
2.8. Western blot (WB) analysis
Fresh frozen tissues from the striatum were collected from mouse
brains after cervical dislocation. Total proteins were extracted with
Radioimmunoprepitation Assay (RIPA) buffer made up by 50 mM Tris-
HCl pH 7.4, 150 mM NaCl, NP-40 1%, sodium deoxycholate 0.1%,
sodium dodecyl sulfate (SDS) 0.1%, 1 mM NaF, 1 mM NaVO4 plus
complete protease inhibitor mixture (Roche Diagnostics, Mannheim,
Germany). Protein concentration in the samples was measured by using
the Bio-Rad DCTM protein assay kit (Bio-Rad Laboratories, Milan,
Italy). Equal amounts of proteins (30 μg) were run on 10% poly-
acrylamide gels and transferred onto polyvinylidene fluoride (PVDF)
membrane. Densitometric analysis of the bands were performed by
using FIJI Software and all bands were normalized to Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) levels as a control of equal loading
of samples in the total protein extracts. For densitometry analysis of
bands, each experimental condition was performed in quadruplicate
and the resulting data were subjected to statistical analysis.
2.9. Real-time PCR
Total RNA was extracted from substantia nigra specimens of C57BL/
6J, C57BL/6JOlaHsd and SYN120 tg mice using an RNA extraction kit
(RNeasy Mini Kit, Qiagen, Hilden, GE) as previously described (Faustini
et al., 2018). Two μg of RNA were retrotranscribed by using QuantiTect
Reverse Transcription Kit (Qiagen) according to the manufacturer's
instructions. Real-time PCR was performed by using SYBR Green Master
Mix (Applied Biosystems, Foster City, USA) and the following primer
pairs: SYN3 for aaatcagcatcaccccaccc, SYN3 rev gccttggcctcatcttcact;
GAPDH for tcaacagcaactcccactctt, GAPDH rev ccagggtttcttactccttgg.
The ViiA7 Real Time PCR system (Life Technologies, Grand Island,
NY, U.S.A.) as used for 40 cycles of 95 °C for 15 s and 60 °C for 1 min.
mRNA expression was normalized to GAPDH gene expression. Each
experimental condition was analyzed in triplicate and the resulting data
were averaged and subjected to statistical analysis.
2.10. Antibodies
A list of the primary antibodies for detection of α-syn, DAT, GAPDH,
Syn III and TH and of their working concentrations in immunofluorescence,
Table 1
List of the primary antibodies used for the study including their characteristics and working dilutions.
Antibody Catalog number Manufacturer Clonality Immunogen Host species Working dilution
WB IF In situ PLA
Alpha-syn (syn1) 610,787 BD Monoclonal aa. 15–123 Mouse 1:1000 1:500
DAT AB2231 Millipore Polyclonal N-terminus Rabbit 1:3000
GAPDH G8795 Sigma-Aldrich Monoclonal Not specified Mouse 1:5000
Syn III 106,303 Synaptic System Polyclonal aa 417–434 Rabbit 1:2000 1:600 1:500
TH AB152 Millipore Polyclonal Not specified Rabbit 1:700
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in situ PLA and WB studies is summarized in Table 1. The secondary an-
tibodies used for fluorescence immunohistochemistry were a goat anti-
mouse IgG Cy3-conjugated, a goat anti-rabbit IgG Cy3-conjugated, a goat
anti-rabbit Alexa488-conjugated and a goat anti-rabbit Alexa405-con-
jugated (Jackson ImmunoResearch, Pennsylvania, USA). The secondary
antibodies used for WB were goat anti-rabbit IgG-HRP or goat anti-mouse
IgG-HRP (Santa Cruz Biotechnology, Dallas, Texas, USA).
2.11. Open field behavioral tests
Acute locomotor activity of C57BL/6J, C57BL/6JOlaHsd, SYN120
tg and Syn III ko mice was assessed using the automated AnyMaze video
tracking system (Stoelting, Wood Dale, IL) according to previously
described protocols (Zaltieri et al., 2015). The total distance travelled
was recorded automatically in the open field arena (50 × 50 cm2) and
data were analyzed in 14 trials of 2.5 min each. Mice were gently
placed in the arena and were allowed to explore freely for 5 min before
starting the test. After 10 min of registration in basal condition, mice
received an i.p. injection of cocaine (10 mg/kg, dissolved in normal
saline 0.9%) (Tocris, Bristol, UK), or MPH (d-threo, 10 mg/kg, dissolved
in normal saline 0.9%) (Tocris), or GBR-12935 (20 mg/kg, dissolved in
normal saline 0.9%) (Tocris), whereas control mice were treated with
vehicle (normal saline 0.9%). To evaluate the effect of MPH or cocaine
independently of their DAT-inhibitory action, the protocol was adapted
as follows. Mice were analyzed for 10 min in basal conditions, then
subjected to an i.p. injection of GBR-12935 (20 mg/kg), registered for
15 min and finally subjected to an i.p. injection of either cocaine
(10 mg/kg) or MPH (10 mg/kg) registering for the following 25 min.
All the experiments were conducted during daylight hours. N = 6/10
animals per group were analyzed for each experimental setting in-
cluding vehicle or drug treatments.
2.12. Acceptor photobleaching fluorescence resonance energy transfer
(FRET) studies
Human neuroblastoma SK-N-SH cells were grown in complete
medium comprising Dulbecco's modified Eagle's medium with 1000 mg
glucose/l (Life technologies, California, USA) supplemented with 10%
heat-inactivated fetal bovine serum, 100 μg/ml penicillin, 100 μg/ml
streptomycin and 0.01 μM non-essential amino acids (Sigma-Aldrich).
Cells were maintained at 37 °C under a humidified atmosphere of 5%
CO2 and 95% O2.
For FRET studies, SK-N-SH cells were seeded onto poli-D-lysine-
coated 13 mm glass coverslips in 24-well plates (15,000 cells per cov-
erslip) and were maintained in differentiation medium for ten days by
daily adding 10 μM retinoic acid to the complete medium. At day 7,
cells were transiently transfected with pGFP-human Syn III (transdu-
cing human green fluorescent protein (GFP)-tagged Syn III and pCMV6-
RFP-α-syn 140 (transducing red fluorescent protein (RFP)-tagged fl α-
syn) or pCMV6-RFP-α-syn 120 (transducing RFP-tagged (1–120) α-syn)
constructs, by using Lipofectamine 3000 (Life Technologies), according
to the manufacturer's instructions. pCMV6-RFP-α-syn 140 or pCMV6-
RFP-α-syn 120 single-transfected cells were used as negative controls
during the FRET experiments. Three days after transfection, cells were
treated for 15 min with vehicle (normal saline 0.9%), 10 μM cocaine,
10 μM MPH (d-threo) or 10 μM GBR-12935, then immediately fixed
with Immunofix for 15 min and subsequently mounted on glass slides.
Fixed cells were analyzed by means of a Zeiss confocal laser mi-
croscope LSM 880 (Carl Zeiss) with the laser set on λ = 488–543.
After identifying double positive cells three-to-six regions of interest
(ROI) were analyzed for 4 series. Two images of basal condition (Pre-
bleaching) were acquired before bleaching the RFP acceptor fluor-
ophore with laser 543 set at 65% power. Then, other two images were
acquired after the bleaching (Post-bleaching).
The FRET efficiency (intended as the GFP recovery after RFP pho-
tobleaching) was measured by using Zen black software (Carl Zeiss).
The average intensity of the background (outside the cell) was sub-
tracted from the average intensity of the ROI and all the FRET values
resulting from the different ROI were used for statistical analysis.
2.13. Molecular modeling of MPH interaction with either fl or C-terminally
truncated α-syn
The frame number 4 of the nuclear magnetic resonance (NMR)
structure of α-syn (2KKW) was used to pursue docking studies by means
of Glide (https://www.schrodinger.com). The protein was prepared
with the protein preparation tool of Maestro (https://www.
schrodinger.com) and the docking grid was centered so as to cover
the whole region where the N-terminal and C-terminal domains are in
close proximity. MPH was prepared with the atom builder tool of
Maestro. Each docking run was carried out using the standard precision
(SP) method and the Van der Waals scaling factor of nonpolar atoms
was set to 0.8. The binding mode having the highest score was selected
after visual inspection. The (1–120) α-syn MPH complex was prepared
starting from the generated model of fl α-syn in complex with MPH. The
fl α-syn was then truncated at the 120th residue and the complex thus
obtained was submitted to a stepwise refinement protocol, where the
complex was refined by applying harmonic constraints that were pro-
gressively reduced until no constraints were applied.
2.14. Statistical analysis
Statistical differences in the protein levels detected by WB or esti-
mated by immunofluorescence and in mRNA expression between groups
(C57BL/6J, C57BL/6JOlaHsd and SYN120 tg mice) were assessed by
using one-way ANOVA followed by Bonferroni's multiple comparisons
test (n = 6 animals for each group for WB and immunofluorescence
analysis and n= 3 animals for each group for qPCR analysis). Statistical
differences between the total distance travelled in the open field test by
the different experimental groups (C57BL/6J, C57BL/6JOlaHsd and
SYN120 tg or Syn III ko and wt mice or SYN120 tg mice injected with
AAV-shSyn III and AAV-shScramble) were assessed by using two-way
ANOVA followed by Bonferroni's multiple comparisons test (n = 6–12
animals for each group). Differences in the mean FRET efficiencies of SK-
N-SH cells were assessed by using one-way ANOVA + Newman-Keuls
post comparison test (n = 15–20 cells for each experimental condition).
Differences in the Syn III immunopositive area in the substantia nigra
between SYN120 tg mice injected with scramble shRNA or shRNA for
Syn III gene silencing were analyzed by Student's t-test. All data are
presented as mean ± standard error of the mean (SEM) and statistical
significance was established at P < 0.05.
3. Results
3.1. Synapsin III deposition and interaction with α-syn in the substantia
nigra
We recently showed that 12-month-old C57BL/6JOlaHsd α-syn null
mice display striatal redistribution and accumulation of Syn III when
compared to C57BL/6J littermate controls (Zaltieri et al., 2015). The
Syn III alterations are even more pronounced in the striatum of 12-
month-old SYN120 tg mice overexpressing C-terminally truncated α-
syn on the C57BL/6JOlaHsd background (Zaltieri et al., 2015), which at
this age exhibit a marked deposition of fibrillary aggregated α-syn as
well as SNAREs and DAT redistribution accompanied by DA release
failure, as we previously showed (Bellucci et al., 2011; Garcia-Reitbock
et al., 2010; Tofaris et al., 2006). Here, we investigated Syn III im-
munolabeling and co-localization with Thioflavin S-positive fibrillary
aggregates in the substantia nigra TH-positive neurons of 12-month-old
SYN120 tg vs. C57BL/6J or C57BL/6JOlaHsd mice in order to evaluate
the presence of Syn III within α-syn aggregates in this brain area. In line
with our previous findings on striatal sections (Zaltieri et al., 2015),
G. Faustini, et al. Neurobiology of Disease 138 (2020) 104789
4
confocal analysis showed accumulation of Syn III in substantia nigra TH-
positive neurons of C57BL/6JOlaHsd α-syn null and even more in those
of SYN120 tg mice, with respect of C57BL/6J littermates (Fig. 1A-C;
Supplementary Fig. 1A). While in the nigral TH-positive cells of α-syn
null mice Syn III immunoreactivity displayed a dot-like sparse dis-
tribution (Fig. 1B, arrows), in those of SYN120 tg mice it exhibited a
more condensed dot-like or mealy-granular appearance (Fig. 1C ar-
rows) and showed a marked co-localization with α-syn (Fig. 1C merge).
In C57BL/6J mice, Syn III staining was poor (Fig. 1A).
We then assessed α-syn and Syn III interaction in the substantia nigra
TH-positive neurons by in situ PLA (Fig. 1D-F), which allows to visualize
protein-protein interactions in intact tissues (Bellucci et al., 2014;
Faustini et al., 2018). We found that 12-month-old C57BL/6J mice
exhibited a basal α-syn/Syn III PLA signal supportive of the occurrence
of Syn III/α-syn interaction (Fig. 1D). The PLA signal was increased in
the nigral TH-positive cells of SYN120 tg mice (Fig. 1F), suggesting an
augmented interaction between C-terminally truncated (1–120) α-syn
and Syn III. The absence of PLA staining in the substantia nigra of
C57BL/6JOlaHsd mice (Fig. 1E) confirmed the specificity of the assay.
As stated above, 12-month-old SYN120 tg mice exhibit α-syn fi-
brillary aggregation in the substantia nigra (Tofaris et al., 2006). Here,
we observed a marked co-localization between Syn III immunolabeling
and Thioflavin S staining in both the substatina nigra and striatum that
supports the presence of Syn III within the fibrillary α-syn aggregates in
the nigrostriatal neurons of these mice (Fig. 2).
3.2. Age-related changes in Syn III and DAT levels in the striatum of
C57BL/6J, C57BL/6JOlaHsd and SYN120 tg mice
The age-dependent changes in α-syn, DAT and Syn III levels in the
striatum of C57BL/6J, C57BL/6JOlaHsd and SYN120 tg mice were as-
sessed at 3, 8, 12 and 16 months of age (Fig. 3) by WB.
In line with our previous findings (Tofaris et al., 2006), we observed
that the expression of C-terminally truncated α-syn in SYN120 tg mice was
lower than fl wt α-syn in the C57BL/6J littermate controls (Fig. 3). Indeed,
the expression of (1–120) α-syn in SYN120 tg mice is under the control of
the rat TH promoter and is thus restricted to striatal dopaminergic term-
inals. The C57BL/6JOlaHsd mice did not show α-syn (Fig. 3).
At 3 months of age, DAT levels were decreased in C57BL/6JOlaHsd
mice when compared to both C57BL/6J and SYN120 tg littermates.
However, this difference was abated in 8-month-old animals (Fig. 3).
We then found that in SYN120 tg mice, DAT levels were significantly
augmented at 12 and 16 months of age, when compared to control
C57BL/6JOlaHsd littermates. This augment in DAT levels cannot be
indicative of increased dopaminergic projections in the striatum, as
supported by the significant decrease of basal and depolarization-de-
pendent DA release and of its main metabolites 3, 4-dihydrox-
yphenylacetic acid (DOPAC) and homovanillic acid (HVA) that we
previously described in the SYN120 tg mice from 12 months of age
(Garcia-Reitbock et al., 2010). It can rather be ascribed to other com-
pensatory mechanisms regulating the DAT in response to DA release
Fig. 1. Immunofluorescence labeling of α-syn and Syn III and in situ
PLA in TH-positive substantia nigra neurons of 12-month-old C57BL/6J,
C57BL/6JOlaHsd and SYN120 tg mice.
A. Mild α-syn and Syn III staining in the TH-positive cells of C57BL/6J
mice. B. Marked accumulation of Syn III (white arrows) within the TH-
positive cells of C57BL/6JOlaHsd mice which did not exhibit α-syn
immunoreactivity. C. Marked accumulation of α-syn and Syn III (white
arrows) in the TH-positive neurons of SYN120 tg mice. Cell nuclei were
counterstained with To Pro. Scale bar 10 μm.
D. Presence of a mild α-syn/Syn III in situ PLA positivity in the TH-
positive neurons of C57BL/6J mice. E. Absence of the α-syn/Syn III in
situ PLA signal in the TH-positive cells of C57BL/6JOlaHsd mice. F. The
accumulation of the α-syn/Syn III in situ PLA reactivity in the TH-po-
sitive neurons of SYN120 tg mice is supportive of the improvement of
α-syn/Syn III interaction. Cell nuclei were counterstained with
HOECHST. Scale bar 10 μm.
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failure or α-syn aggregation. Consistently, in line with the results we
report here and our previous findings (Bellucci et al., 2011), a recent
study showed the occurrence of DAT upregulation and α-syn/DAT
complexes formation as early pathological events in non-human pri-
mates who received putaminal injection of α-syn preformed fibrils and
exhibiting loss of nigrostriatal neurons (Chu et al., 2019).
We then observed that, at 3, 8 and 12 months of age, the absence of α-
syn induced a statistically significant increase of Syn III in C57BL/6JOlaHsd
mice when compared to the C57BL/6J littermates. At 3 and 8 months of
age, the levels of Syn III were reduced in SYN120 tg mice when compared to
C57BL/6JOlaHsd littermates, suggesting that the presence of α-syn, even if
in the truncated form, may attenuate the massive increase of Syn III. This
notwithstanding, SYN120 tg mice exhibited a progressive increase of Syn III
levels which was comparable to that of C57BL/6JOlaHsd animals at later
time points (Fig. 3). Since aggregation of (1–120) α-syn has been detected
from 6 months of age in the brains of SYN120 tg mice (Tofaris et al., 2006),
it is feasible that the early down-regulation of Syn III levels in the striatum
may be ascribed to the enhanced production of soluble C-terminally trun-
cated α-syn which might later lose this action when fibrillation begins.
To further corroborate whether the expression of C-terminally
truncated α-syn on the C57BL/6JOlaHsd background could quench Syn
III expression similarly to wt protein in C57BL/6J mice, we assessed
Syn III mRNA levels by real-time quantitative PCR at 3 and 12 months
of age (Supplementary Fig. 1B). At 3 months of age, the expression of
Syn III mRNA was significantly increased in C57BL/6JOlaHsd mice
when compared to wt mice. In parallel, Syn III expression in the
SYN120 tg mice was decreased vs C57BL/6JOlaHsd and increased vs
C57BL/6J littermates, but these changes did not result statistically
significant. At 12 months of age, the differences in relative Syn III
mRNA expression observed between C57BL/6J, C57BL/6JOlaHsd and
SYN120 tg mice mirrored the changes in protein levels detected by WB
(Supplementary Fig. 1B).
Although the decrease of Syn III mRNA observed in SYN120 tg mice
at 3 months of age did not exactly retrace the reduction of the protein,
as detected by WB, it is known that mRNA amount will not always
reflect the level of the encoded protein. Indeed, the amount of mRNA
within a cell is determined by the ratio of its synthesis and degradation
rates, which are finely regulated processes (Mattick, 2004). Moreover,
Fig. 2. Syn III immunolabeling coupled with Thioflavin S staining in the substantia nigra and striatum of 12-month-old C57BL/6J, C57BL/6JOlaHsd and SYN120 tg
mice.
A. Marked accumulation of the Thioflavin S signal, indicative of protein fibrillation, in co-localization with Syn III immunopositive labeling in the substantia nigra of
SYN120 tg mice. B. Marked Syn III and Thioflavin S co-localizing signals were also observed in the striatum of SYN120 tg mice. Please note that asterisks are located
nearby non-specific lipofuscin signal. Scale bar A: 100 μm, B: 10 μm.
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WB analysis was conducted on striatal samples, while for qPCR ex-
periments we used substantia nigra samples, as synapsins are synthe-
sized in neuronal soma and then transferred to terminals through ax-
onal transport (Tang et al., 2013).
3.3. Alpha-synuclein and Syn III interplay influences the locomotor response
to MPH
We then wanted to expand our previous studies on the effect of
cocaine administration in 12-month-old wt and C57BL/6JOlaHsd mice
(Zaltieri et al., 2015) in order to evaluate the effect of different MRIs in
these mouse lines and SYN120 tg animals at the time points used for the
investigation of striatal proteins levels. In particular, we analyzed the
acute locomotor response to the i.p. administration of cocaine (10 mg/
kg), MPH (10 mg/kg, d-threo), GBR-12935 (20 mg/kg) or vehicle in
C57BL/6J, C56BL/6JOlaHsd and SYN120 tg mice by using the open
field behavioral paradigm (Zaltieri et al., 2015). We registered the
distance travelled by mice in 2.5 min intervals for 10 min in basal
condition and for 25 min after the i.p. administration of the drugs.
At 3 months of age, C57BL/6J mice exhibited a significant im-
provement of locomotion after cocaine administration, while C57BL/
6JOlaHsd mice did not respond (Fig. 4A), in agreement with the fact
Fig. 3. Analysis of the levels of α-syn, DAT and Syn III in the striatum of C57BL/6J, C57BL/6JOlaHsd and SYN120 tg mice at 3, 8, 12, 16 months of age.
The expression of (1–120) α-syn in SYN120 tg mice resulted lower than that of endogenous wt α-syn in C57BL/6J littermate controls at all the time point analyzed
(### P < 0.001, One-way ANOVA + Bonferroni's post-comparison test). C57BL/6J exhibited a statistically significant difference in α-syn immunopositivity when
compared to C57BL/6JOlaHsd littermates which did not exhibit α-syn immunopositivity (*** P < 0.001, One-way ANOVA + Bonferroni's post-comparison test).
Three-month-old C57BL/6JOlaHsd mice displayed decreased DAT levels when compared to both C57BL/6J (*** - 52.66%, P < 0.001, One-way ANOVA +
Bonferroni's post-comparison test) and SYN120 tg mice (°°° -55.78%, P < 0.001, One-way ANOVA + Bonferroni's post-comparison test). These differences were lost
at 8 months of age. The levels of DAT resulted significantly increased in 12- and 16-month-old SYN120 tg mice when compared to C57BL/6JOlaHsd littermates
(°°° + 53.73%, P < 0.001 and ° + 79.04%, P < 0.05, One-way ANOVA+ Bonferroni's post-comparison test). A significant increase of Syn III levels was observed in
C57BL/6JOlaHsd mice when compared to C57BL/6J littermates at 3, 8 and 12 months of age (* + 87.65%, P < 0.05 at 3 months and *** + 82.86% at 8 months,
*** + 68.38% at 12 months, P < 0.001, One-way ANOVA + Bonferroni's post-comparison test). At 3 and 8 months of age, the levels of Syn III in SYN120 tg mice
were comparable to those of C57BL/6J littermates, but resulted significantly reduced when compared to C57BL/6JOlaHsd mice (° - 103.5%, P < 0.05 at 3 months
and °° - 54.54%, P < 0.01 at 8 months, One-way ANOVA + Bonferroni's post-comparison test). This notwithstanding, at 12 and 16 months SYN120 tg mice showed
an age-related increase in Syn III levels, which returned comparable to those of C57BL/6JOlaHsd mice but were significantly augmented when compared to C57BL/
6J littermates (### + 106.3%, P < 0.001 at 12 months and # + 88.57%, P < 0.05 at 16 months, One-way ANOVA + Bonferroni's post-comparison test).
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that they display both reduced DAT levels and a marked increase of Syn
III. Interestingly, 3-month-old SYN120 tg mice showed a significantly
higher locomotor activity 5, 7.5 and 10 min after cocaine administra-
tion when compared to C57BL/6JOlaHsd littermates. This suggests
that, in spite of the C57BL/6JOlaHsd background, the expression of C-
terminally truncated α-syn in TH-positive neurons of 3-month-old
SYN120 tg mice sustained a mild response to cocaine.
In agreement with the WB data, supporting a rebalance of DAT le-
vels in the three mouse lines at 8 months of age, we found that C57BL/
6JOlaHsd mice exhibited a statistically significant increase in the dis-
tance travelled in the interval between 7.5 and 17.5 min after cocaine
administration, when compared to SYN120 tg mice, which lost the mild
locomotor response observed at 3 months of age. The increase in mo-
tility observed in 8-month-old C57BL/6JOlaHsd mice following cocaine
administration, that was not detected in the animals at 3 months of age,
may be ascribed to striatal DAT increase in conjunction with elevated
Syn III levels, as these proteins can additively contribute to raise the
response to this drug. Indeed, Kile and co-authors showed that only
single Syn III ko mice exhibit enhanced striatal dopaminergic functions
but in parallel that cocaine-stimulated DA release is reduced in synapsin
I/II/III triple ko animals (Kile et al., 2010). This supports that, although
Syn III is the only synapsin exerting a negative regulatory control of DA
release in the striatum, cocaine effect is reduced in the absence of Syn III
but can instead be enhanced by the increase of this protein. This out-
come may have worked in concert with a more marked cocaine-induced
DA re-uptake inhibition related to DAT increase to uplift the locomotor
response of the α-syn null mice at 8 months of age.
In line with this hypothesis and our previous observations (Zaltieri
et al., 2015), when we studied the locomotor response to cocaine ad-
ministration at 12 months of age, we found that C57BL/6JOlaHsd mice
exhibited a delayed increase in their peak of motility, which however
was significantly higher vs that observed in C57BL/6J wt mice, and
rapidly dropped in the interval between 15 and 17.5 min after cocaine
administration. This supports that, with the prolonged absence of α-
syn, the kinetic of Syn III-dependent DA release may differ from the
standard DAT-mediated effect. Again, 12-month-old SYN120 tg mice
did not respond to cocaine administration, supporting that the sig-
nificant increase of striatal DAT levels is not sufficient to recover the
response to cocaine. This may be explained by the fact that these mice
show a marked reduction of striatal DA release as well as alterations in
the distribution of Syn III, DAT and SNARE proteins (Bellucci et al.,
2011; Garcia-Reitbock et al., 2010; Zaltieri et al., 2015).
At 16 months of age, C57BL/6JOlaHsd mice lost their ability to
respond to the acute cocaine treatment, suggesting that they lost their
dopaminergic striatal functions along aging. Indeed, nigrostriatal neu-
rons from α-syn ko mice may exhibit a lower vulnerability threshold
during aging. In particular, they show reduction of TH-positive fibers in
the striatum and decrease of striatal levels of TH and DAT accompanied
by decrease of DA and its metabolites, without any change in the
overall number of TH-positive neurons in the substantia nigra (Al-Wandi
et al., 2010; Connor-Robson et al., 2016). Finally, we found that the
locomotor response of 16-month-old C57BL/6J and SYN120 tg mice
was almost comparable to that observed at 12 months of age.
We then studied the motor response of mice to MPH administration
(Fig. 4B). At 3 and 8 months of age, SYN120 tg, C57BL/6JOlaHsd and
C57BL/6J mice similarly responded to MPH administration in spite of
the differences in DAT and Syn III levels (Fig. 4B). Surprisingly, at
12 months of age, SYN120 tg mice manifested a paradoxical and sta-
tistically significant motility increase when compared to C57BL/6J and
C57BL/6JOlaHsd littermates, which showed comparable behaviors.
The hyper-response to MPH administration of SYN120 tg mice persisted
at 16 months of age, when also C57BL/6J mice exhibited a mild peak in
the locomotor response in the first ten minutes following MPH ad-
ministration, while C57BL/6JOlaHsd mice showed the same kind of
motility observed at younger ages. These findings support that the lo-
comotor response to MPH administration is enhanced in the presence of
C-terminally truncated α-syn aggregates, when these are occurring in
parallel to the increase of Syn III and DAT, in spite of the co-aggregation
of these proteins with α-syn.
In order to estimate the exact contribution of DAT inhibition to the
locomotor response of mice along aging, we also evaluated their mo-
tility following GBR-12935 administration (Supplementary Fig. 2A). In
line with the decreased DAT levels observed in C57BL/6JOlaHsd and
with our previous observation (Bellucci et al., 2011), we found a de-
creased activity of C57BL/6JOlaHsd and SYN120 tg mice when com-
pared to C57BL/6J control mice at all the time point analyzed. This
suggests that the formation of α-syn/DAT inclusions induces an im-
pairment of DAT trafficking in SYN120 tg mice. Indeed, in line with
evidence supporting a direct interaction between the central region of
α-syn (aa 61–95) and DAT C-terminus (Lee et al., 2001), we and others
have shown that α-syn affects DAT surface expression (Adamczyk et al.,
2006; Bellucci et al., 2008; Chu et al., 2019; Fountaine and Wade-
Martins, 2007; Wersinger and Sidhu, 2003; Wersinger and Sidhu,
2005). Among the synucleins, α-syn results the most efficient in nega-
tively regulating physiological DAT transport to the plasma membrane
(Oaks et al., 2013). Therefore, although we observed increased levels of
DAT in SYN120 tg mice vs α-syn null littermates, the lower response to
GBR-12935 that they exhibited could result from an α-syn-induced
decrease of DAT membrane transport efficiency occurring in response
to (1–120) α-syn expression on the C57BL/6JOlaHsd α-syn null back-
ground, that may have been worsened by the progressive aggregate
formation.
During all the behavioral tests, parallel groups of C57BL/6J, C57BL/
6JOlaHsd and SYN120 tg mice were injected with vehicle (normal
Fig. 4. Effect of cocaine or MPH administration on the locomotor activity of C57BL/6J, C57BL/6JOlaHsd and SYN120 tg mice at 3, 8, 12 and 16 months of age.
A. Cocaine differentially affected the locomotor response of C57BL/6J, C57BL/6JOlaHsd and SYN120 tg mice at all the time point analyzed (3 months: interaction:
F26,180 = 3.139: 8 months: interaction: F26,210 = 2.652, P < 0.0001; 12 months: interaction: F65,286 = 7.120, P < 0.0001; 16 months: interaction: F26,340 = 2.538
P < 0.001). At 3 and 16 months of age C57BL/6J mice showed an enhanced locomotor response to cocaine vs C57BL/6JOlaHsd (*** P < 0.001, ** P < 0.01, *
P < 0.05) or SYN120 tg littermates (# P < 0.05, ## P < 0.01, ### P < 0.001). At 3 months of age these latter showed a mild statistically significant increase in
the locomotor response to cocaine vs C57BL/6JOlaHsd mice (° P < 0.05, °° P < 0.01). At 8 months of age, the locomotor response of C57BL/6JOlaHsd mice to
cocaine administration was comparable to that observed in C57BL/6J animals, but out matched that of SYN120 tg mice (° P < 0.05, °° P < 0.01). Twelve-month-
old C57BL/6JOlaHsd mice exhibited a significant increase in the locomotor response to cocaine vs wt littermates (*** P < 0.001, ** P < 0.01, * P < 0.05) and
SYN120 tg mice (° P < 0.05, °° P < 0.01, °°° P < 0.001). Finally, at 16 months of age only C57BL/6J mice were able to display a locomotor response to cocaine
administration and exhibited significant differences vs both C57BL/6JOlaHsd (*** P < 0.001, * P < 0.05) and SYN120 tg mice (### P < 0.001), which showed
comparable feedbacks.
B. MPH differentially affected the locomotor response of C57BL/6J, C57BL/6JOlaHsd and SYN120 tg mice at all the time point analyzed (3 months: interaction:
F26,210 = 1.553, P < 0.05; 8 months: interaction: F26,82 = 0.2541; 12 months: interaction: F26,210 = 3.901, P < 0.0001; 16 months: interaction: F26,405 = 2.299
P < 0.001). At 3 months of age C57BL/6J mice exhibited a mild increase in MPH-stimulated motility vs C57BL/6JOlaHsd (* P < 0.05) and SYN120 tg mice (#
P < 0.05, ## P < 0.01), which behaved similarly. At 8 months of age, the three mouse lines showed similar responses. At 12 and 16 months of age SYN120 tg mice
exhibited a statistically significant improvement in the locomotor response to MPH administration vs C57BL/6J (# P < 0.05, ## P < 0.01 and ### P < 0.001)
and C57BL/6JOlaHsd littermates (°° P < 0.01 and °°° P < 0.001). Sixteen-month-old C57BL/6J mice showed a brief statistically significant increase in the
locomotor response at 5 and 7.5 min from MPH injection when compared to C57BL/6JOlaHsd mice (** P < 0.01 and *** P < 0.001).
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saline 0.9%) and analyzed. These mice showed a locomotor response
that had similar basal conditions, supporting that the vehicle injection
did not influence their motility (Supplementary Fig. 2B).
To further clarify the relevance of DAT blockade in cocaine- or
MPH-induced locomotor activity, we analyzed the motility of 12-
month-old mice after GBR-12935 administration, followed by either
cocaine or MPH treatment (Fig. 5A,B). GBR-12935 pre-administration
was used to induce DAT blockade, in order to ensure that the locomotor
response observed after cocaine or MPH was independent of DAT in-
hibition. We found that SYN120 tg mice neither responded to GBR-
12935, nor to the subsequent cocaine administration. C57BL/6J and
C57BL/6JOlaHsd mice positively responded to GBR-12935 and showed
a fast peak in motor activity 2.5 min after cocaine treatment, followed
by different time-dependent attenuation (Fig. 5A). This phenomenon
may be the result of a compensatory decrease of DA release deriving
from an overstimulation of striatal D2 autoreceptors in response to the
marked increase of extra-synaptic DA resulting from the additive effect
of GBR-12935 and cocaine. The analysis of the total distance travelled
in the three different experimental tranches (basal condition, GBR-
12935 single administration, cocaine administration following GBR-
12935) confirmed the above results (Fig. 5B).
When we analyzed the locomotor response to MPH administration
after GBR-12935 (Fig. 5A), we found that SYN120 tg mice still ex-
hibited an enhanced locomotion starting 5 min after MPH treatment.
These findings suggest that the MPH-mediated stimulation of locomotor
activity in SYN120 tg mice does not depend on DAT inhibition, which
was achieved by GBR-12935-operated blockade, but rather on the pa-
thological α-syn/Syn III interplay. In support of this, the motor response
of C57BL/6J control mice resulted comparable to that observed after
GBR-12935 plus cocaine injection, and C57BL/6JOlaHsd animals only
showed a mild but not significant motility increase 10 min after MPH
administration. The analysis of the total distance travelled in the dif-
ferent experimental tranches confirmed these results (Fig. 5B).
To evaluate the relevance of Syn III in the motor response to MPH,
cocaine or vehicle administration, we performed the open field tests in
12-month-old Syn III ko and C57BL/6J mice (Fig. 5C, Supplementary
Fig. 3A). We found that Syn III ko mice did not exhibit any improvements
of motility after the administration of these drugs. This observation
collimates with findings indicating that the ability of cocaine to enhance
DA release is reduced in the absence of Syn III (Kile et al., 2010).
Finally, we probed whether the enhanced locomotor response to
MPH administration observed in aged SYN120 tg mice could effectively
be mediated by a cooperative action of α-syn and Syn III. To this purpose,
12-month-old SYN120 tg mice were subjected to AAV-mediated Syn III
gene silencing and the locomotor response of these mice after an acute
MPH challenge was evaluated at 16 months of age (Fig. 5D).
Quantification of Syn III immunolabeling in the substantia nigra of mice
showed a statistically significant reduction of Syn III-positive area in the
animals which were injected with the AAV transducing the Syn III shRNA
(Supplementary Fig. 3B,C). Remarkably, the animals subjected to Syn III
gene silencing lost the capability to respond to MPH administration,
while those injected with the AAV transducing scramble shRNA se-
quences could still respond to the drug. This observation confirms that
Syn III is implicated in MPH action. In light of our previous findings
showing that 12 and 16-month-old C57BL/6JOlaHsd mice, that express
elevated Syn III levels in the absence of α-syn, did not exhibit the
paradoxical increase in locomotion observed in SYN120 tg mice, the
latter results further suggest that MPH-mediated stimulation of loco-
motor activity may be co-orchestrated by α-syn and Syn III pathological
cooperation.
3.4. MPH stimulates the interaction between Syn III and fl or (1–120)
human α-syn
To better understand how cocaine, MPH (d-threo) or GBR-12935
could affect the interplay between α-syn and Syn III, we evaluated
whether an acute 15 min treatment with these compounds could affect
the interaction between either fl or (1–120) α-syn and Syn III by using
acceptor photobleaching FRET (Fig. 6A), in a cell culture system re-
producing α-syn/Syn III inclusion formation. Acceptor photobleaching
FRET microscopy allows an accurate evaluation of protein-protein in-
teraction through the measurement of FRET efficiency. This parameter
is indicative of the increase of donor fluorescence after complete pho-
tobleaching of the acceptor fluorescence, within a FRET pair of fluor-
ophores (where the emission wavelength of a donor falls within the
excitation wavelength of an acceptor). Since FRET efficiency is de-
tectable only when the two fluorophores are sufficiently close to ensure
that their linked proteins are interacting, the molecular proximity of
these latter results strictly dependent on this parameter (Bajar et al.,
2016; Ishikawa-Ankerhold et al., 2012).
In particular, we used SK-N-SH cells overexpressing GFP-tagged Syn
III (Syn III-GFP) together with either RFP-tagged fl α-syn (flα-syn-RFP)
or RFP-tagged (1–120) α-syn-RFP (120α-syn-RFP) that, in line with
previous findings (Fares et al., 2016), can lead to the formation of in-
soluble intracellular inclusions composed of either fl or C-terminally
truncated α-syn. Negative controls were also performed to confirm the
specificity of FRET signal. In particular, in order to assess that GFP
signal recovery was directly dependent on RFP bleaching, FRET effi-
ciency was measured on cells with the sole RFP-α-syn transfection.
Results (not shown) supported the absence of photobleaching recovery
in single RFP-α-syn-transfected cells.
By confocal microscopy we observed that SK-N-SH cells transducing
Fig. 5. Cocaine- and MPH-induced locomotor responses after GBR-12935 pretreatment in 12-month-old C57BL/6J, C57BL/6JOlaHsd and SYN120 tg mice.
A. Two-way ANOVA showed that the three mouse lines exhibited a differential locomotor response to the sequential administration of either GBR-12935 + cocaine
(interaction: F38,321 = 4.211, P < 0.0001) or GBR-12935 + MPH (interaction: F38,643 = 9.7, P < 0.0001). After GBR-12935 administration we detected a
decreased locomotor activity in C57BL/6JOlaHsd (* P < 0.05, ** P < 0.01, *** P < 0.001) and SYN120 tg mice (# P < 0.05, ## P < 0.01, ### P < 0.001) vs
to C57BL/6J littermates. After cocaine stimulation C57BL/6J showed a peak of motility that was significantly higher than that observed in SYN120 tg (###
P < 0.001) and C57BL/6JOlaHsd mice (***P < 0.001), but then rapidly dropped to basal levels. After cocaine administration the motility of C57BL/6JOlaHsd
resulted significantly augmented when compared to SYN120 tg (°°° P < 0.001) and C57BL/6J mice (* P < 0.05 and *** P < 0.001). In C57BL/6J mice MPH
induced a quick motility increase vs C57BL/6JOlaHsd (*** P < 0.001) and SYN120 tg mice (### P < 0.001), which rapidly dropped to basal values. MPH
significantly enhanced the motility of SYN120 tg mice vs C57BL/6J (### P < 0.001) and C57BL/6JOlaHsd mice (°° P < 0.01 and °°° P < 0.001).
B. Statistically significant decrease of the locomotor activity of C57BL/6JOlaHsd (* P < 0.05, ** P < 0.01) and SYN120 tg mice (# P < 0.05) after GBR-12935
stimulation vs C57BL/6J littermates. Cocaine administration improved C57BL/6JOlaHsd mice motility vs C57BL/6J (** P < 0.01) and SYN120 tg animals (°
P < 0.05). MPH-induced locomotor activity was instead enhanced in SYN120 tg mice vs C57BL/6J (### P < 0.001) and C57BL/6JOlaHsd mice (°°° P < 0.001).
C. Graphs are showing the locomotor response to either cocaine or MPH administration of 12-month-old C57BL/6J wt and Syn III ko mice. Two-way ANOVA showed
a significant difference in the locomotor response of these mouse lines (cocaine: interaction: F13,56 = 2.250, P < 0.05 and MPH: interaction: F13,40 = 2.103,
P < 0.05). Syn III ko mice did not respond to either cocaine or MPH administration (* P < 0.05, ** P < 0.01, *** P < 0.001 vs C57BL/6J).
D. Graphs are showing the locomotor response to MPH administration of 16-month-old SYN120 mice which were subjected to bilateral gene silencing of Syn III in the
substantia nigra. Two-way ANOVA showed a significant difference (interaction: F13,84 = 8.207, P < 0.0001) in the locomotor response of these SYN120 tg mice
who were injected with the AAV transducing Syn III shRNA (SYN120 tg AAV-shSyn III) or scramble-AAV (SYN120 tg AAV-shScramble). The injection of a sh-AAV
producing Syn III gene silencing significantly reduced the MPH-induced locomotor activity in SYN120 tg mice, when compared to the littermates SYN120 tg animals
injected with a scramble-AAV (* P < 0.05, ** P < 0.01, *** P < 0.001).
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Fig. 6. FRET-based analysis of fl α-
syn/Syn III and (1–120) α-syn/Syn III
interaction in SH-N-SK cells.
A. Schematic representation of the
acceptor photobleaching FRET experi-
mental set up used to investigate the
interaction between Syn III-GFP with
either flα-syn-RFP or 120α-syn-RFP.
Before the bleaching (Pre-bleaching)
energy is transferred from the donor to
the acceptor fluorophore, after the
bleaching of the acceptor (Post-
bleaching) the increase in donor
fluorescence is measured and the FRET
efficiency is dependent on the mole-
cular proximity.
B. Representative images of SK-N-SH
transducing both flα-syn-RFP and Syn
III-GFP before (upper panels) and after
(lower panels) RFP photobleaching.
C. Representative images of SK-N-SH
transducing both 120α-syn-RFP and
Syn III-GFP before (upper panels) and
after (lower panels) the RFP photo-
bleaching.
D. Histograms are showing the FRET
efficiency of flα-syn-RFP with Syn III-
GFP and of 120α-syn-RFP with Syn III-
GFP in basal condition or registered
15 min after MPH, cocaine or GBR-
12935 administration (* P < 0.05; **
P < 0.01, *** P < 0.001, One-way
ANOVA + Newman-Keuls post-com-
parison test).
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either flα-syn-RFP or 120α-syn-RFP and Syn III-GFP exhibited in-
tracellular round-shaped inclusions which resulted positive for both
RFP and GFP (Fig. 6B,C), thus supporting that they contained either
both fl α-syn and Syn III or both (1–120) α-syn and Syn III. By FRET
analysis, we then found that the fl α-syn and Syn III or (1–120) α-syn
and Syn III co-transfected cells treated with vehicle for 15 min showed a
basal % FRET efficiency of 5.7 ± 0.62 and 3.27 ± 0.22, respectively
(Fig. 6D). Notably, 15 min of MPH treatment significantly increased the
interaction between fl α-syn and Syn III when compared to the cells in
basal condition or to those treated with cocaine or GBR-12935
(Fig. 6D). Remarkably, MPH resulted even more efficient in improving
the interaction between Syn III and (1–120) α-syn vs the respective
vehicle treated controls or to the cells that were treated with cocaine or
GBR-12935 (Fig. 6D). Cocaine mildly improved the interaction between
Syn III and (1–120) α-syn when compared to the vehicle-treated cells,
although with an efficacy that was almost the half of MPH, but had no
effect on Syn III /fl α-syn binding. Finally, GBR-12935 did not affect the
interaction between Syn III and either fl or (1–120) α-syn (Fig. 6D).
4. Discussion
The results of this study support that in the presence of α-syn/Syn III
co-aggregates, specific α-syn conformational variants can contribute to
foster a Syn III-dependent locomotor response to MPH. In particular,
our FRET studies in SK-N-SH cells containing α-syn and Syn III-positive
inclusions, support that MPH promotes the interaction between fl or
(1–120) α-syn and Syn III, suggesting that the establishment of a
functional binding between α-syn and Syn III is necessary to mediate
the stimulatory action of this drug.
As observed in the post mortem brains of PD patients (Longhena
et al., 2018) and in an AAV-based mouse model of PD (Faustini et al.,
2018), we found that Syn III forms fibrillary co-aggregates with C-
terminally-truncated α-syn also in the brain of SYN120 tg mice. When
we analyzed the levels of Syn III in the striatum of C57BL/6J, C57BL/
6JOlaHsd α-syn null and SYN120 tg mice along aging, we found that it
was highly expressed in the brain of mice lacking α-syn, especially at 8
and 12 months of age, but not in C57BL/6J wt littermates. Surprisingly,
at 3 and 8 months of age, the levels of Syn III in the striatum of SYN120
tg mice were lower than in α-syn null littermates, but then raised at
later time points. In line with our previous findings supporting a ne-
gative modulatory action of α-syn on Syn III expression (Zaltieri et al.,
2015), this observation may indicate that the production of C-termin-
ally truncated α-syn on the C57BL/6JOlaHsd background results in a
compensatory down-regulation of Syn III in young SYN120 tg mice.
This is then lost along aging when most of α-syn is aggregated and the
levels of Syn III are increased.
Fig. 7. In-silico simulation of MPH and fl or (1–120) α-syn interaction.
A. Cartoon representation of α-syn fl (1–140) and α-syn-Δ120–140 (1–120). The N-Terminal domain (residues 1–60), the central hydrophobic region (residues
61–95) and the C-terminal domain (residues 96–140/120) are colored in blue, yellow and red, respectively. Both 3-D (green sticks) and 2-D structure of d-threo-MPH
are depicted.
B. MPH (as green, red and blues spheres) in complex with fl α-syn (as surface color coded accordingly to residue charges, where red indicates negatively charged
residues, blue positively charged residues and white hydrophobic residues). The Lys110 and Asp119–120 are highlighted in black circles. C. MPH (as green, red and
blues spheres) in complex with α-syn-Δ120–140 (as surface color coded accordingly to residue charges, where red indicates negatively charged residues, blue
positively charged residues and white hydrophobic residues). (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of this article.)
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Quantitative PCR studies in the substantia nigra of mice at 3 and
12 months of age showed that Syn III mRNA expression in this area
fairly recapitulated the changes in protein levels observed in the
striatum, thus further confirming the existence of a reciprocal regulatory
interplay between the expression of α-syn and syn III.
By analyzing the motility of C57BL/6J, C57BL/6JOlaHsd α-syn null
and SYN120 tg mice after the acute cocaine, MPH or GBR-12935 ad-
ministration, although these are all known to act as DAT blockers, we
found peculiar differences in the locomotor response of the three mouse
lines. In particular, only C57BL/6J mice positively and similarly re-
sponded to cocaine, MPH and GBR-12935, while α-syn null and
SYN120 tg mice were almost insensitive to GBR-12935 administration.
This notwithstanding, they exhibited a differential age-related motility
profile after the i.p. injection of cocaine or MPH. While the motility of
SYN120 tg mice was almost unaffected by cocaine administration at all
the time points analyzed, C57BL/6JOlaHsd mice exhibited a marked
response at 8 and 12 months of age, when the levels of Syn III were
higher, but those of DAT protein were comparable to C57BL/6J mice.
This effect was partially attenuated by the pre-administration of GBR-
12935, supporting that only part of the cocaine-stimulated response of
α-syn null mice is dependent on DAT inhibition. However, these ani-
mals lost their capability to respond to cocaine at 16 months of age,
probably because the differences in Syn III expression levels, when
compared to C57BL/6J mice, become milder at this time point.
We previously showed that cocaine treatment prevents the forma-
tion of α-syn-positive inclusions in cells exposed to glucose deprivation,
an insult stimulating α-syn aggregation (Bellucci et al., 2008). Cocaine
can bind the α-syn N-terminus, acts as an α-syn modulator and induces
a conformational shift of the protein (Jakova and Lee, 2017; Kakish
et al., 2015). Moreover, cocaine abuse increases α-syn in dopaminergic
neurons or in the striatum (Mash et al., 2003; Qin et al., 2005) and α-syn
has been found to be critical for cocaine preference (Trubetckaia et al.,
2019). The present results support that elevated Syn III levels are cru-
cial for allowing cocaine response in the absence of α-syn and that
cocaine is not able to affect the motor response of mice when α-syn is
aggregated. This suggests that 1) cocaine-stimulated locomotor re-
sponse is partly dependent on Syn III and 2) α-syn conformational state
is critical for enabling cocaine binding and the consequent motor ef-
fects.
By analyzing the locomotor activity of mice in response to MPH
administration, we found that C57BL/6J and C57BL/6JOlaHsd mice
exhibited similar responses at 3, 8 and 12 months of age. At 3 and
8 months of age, also the locomotor response of SYN120 tg mice fol-
lowing MPH administration was comparable to that observed in
C57BL/6J and C57BL/6JOlaHsd mice. Though unexpectedly, SYN120
tg mice exhibited an over-increase in the locomotor response, which
resulted markedly enhanced with respect to that of the other mouse
lines, at 12 and 16 months of age. Strikingly, this over-response was not
perturbed by GBR-12935-mediated DAT inhibition and was lost in mice
subjected to Syn III gene silencing. This suggests that the increased
locomotor response observed in SYN120 tg mice following MPH treat-
ment is not dependent on DAT blockade, but is rather crucially medi-
ated by Syn III.
We also observed that Syn III ko mice did not respond to cocaine or
MPH administration, although they did not display differences in DAT
striatal levels (Faustini et al., 2018). This is fully in line with previous
findings showing that cocaine reduces striatal DA release in these mice
(Kile et al., 2010) and sustains that cocaine and MPH effect is
dependent on the presence of Syn III. However, the Syn III-mediated
locomotor activity can be alternatively influenced in the absence or in
the presence of different α-syn conformational variants.
The observation that aged SYN120 tg mice, which show elevated α-
syn aggregation, acquire the ability to respond to MPH treatment, is
reminiscent of the fact that MPH efficiently counteracts freezing of gait
and hypokinesia in advanced PD patients (Delval et al., 2015; Devos
et al., 2007; Moreau et al., 2012; Nikolai Gil et al., 2018; Pollak et al.,
2007). This effect does not rely on the increase in attentional perfor-
mance (Delval et al., 2015) and, although it can enhance L-DOPA ef-
ficacy (Camicioli et al., 2001), it does not necessarily require exogenous
L-DOPA (Pollak et al., 2007). It has been also observed that MPH can
redistribute DA vesicle pools (Sandoval et al., 2003). In light of our
results, we may speculate that the MPH-associated trafficking of sy-
naptic vesicles in dopaminergic neurons could be mediated by α-syn/
Syn III interplay, as these proteins can both control synaptic vesicle
pools (Burre, 2015; Cesca et al., 2010). MPH has demonstrated ther-
apeutic efficacy in ADHD (Huss et al., 2017), a neurodevelopmental
disorder whose onset has been found to positively correlate with the
631C > G Syn III polymorphism (Kenar et al., 2013), which can
contribute to the efficacy of MPH itself (Basay et al., 2016). Our group
has also shown that Syn III is a crucial mediator of early neuronal de-
velopment, migration and orientation (Perlini et al., 2015; Piccini et al.,
2015), findings that further support that Syn III polymorphisms may
significantly contribute to the neurodevelopmental change underlying
ADHD. Interestingly, ADHD patients manifest a psychostimulant-med-
ication independent predisposition to develop disorders of the basal
ganglia, including PD and LB dementia (Curtin et al., 2018; Golimstok
et al., 2011). Moreover, a recent study supports that the rs356219
genotype in SNCA may affect α-syn function and contribute to the
etiology of ADHD (Gerlach et al., 2019). These findings corroborate the
existence of a crucial link between Syn III and α-syn in the pathophy-
siology of LB disorders and possibly of ADHD.
Cocaine and MPH have been found to bind α-syn. In particular, the
former binds the N-terminus of α-syn and prompts the formation of
more compact protein conformation, while the latter promotes loop-
like α-syn folding through a contemporaneous strong N-terminal and
weak C-terminal interaction (Kakish et al., 2015). Cocaine and MPH can
increase or decrease DA neurotransmission by blocking reuptake and
reducing exocytotic release, respectively (Federici et al., 2014). More-
over, while cocaine can stimulate Syn III-dependent DA release in-
dependently of Calcium concentrations (Kile et al., 2010), MPH can
influence α-syn-mediated DA overflow and presynaptic compartmen-
talization, but its effect on DA reuptake is independent of α-syn
(Chadchankar et al., 2012). Our results support that cocaine action is
not significantly influenced by the pathological α-syn/Syn III interplay,
which however actively contributes to the effect of MPH.
It has been shown that, in pathological conditions, α-syn can form
metastable cytotoxic oligomers which give raise to the formation of the
insoluble fibrils composing LB (Longhena et al., 2019). In such cases,
following a basic aggregation mechanism (Chiti and Dobson, 2006), it
has been hypothesized that the central hydrophobic core (residue
61–95) adopts in-register β-sheets conformations, promoting fibril for-
mation (Tuttle et al., 2016). Interestingly, by concurrently binding both
the N- and C-termini of α-syn (but not the central region), MPH inter-
acts with α-syn in such a way that stabilizes the protein in a con-
formation less prone to aggregate and can thus be considered neuro-
protective (Kakish et al., 2015). The NMR structure of α-syn previously
Fig. 8. Schematic representation of the mechanisms and behavioral readout of the differential effect of cocaine and MPH in C57BL/6J, C57BL/6JOlaHsd and SYN120
tg mice at 12 months of age.
Syn III and α-syn are both involved in mediating the motor response to cocaine and MPH. Cocaine stimulated the motility of α-syn null mice, which showed elevated
Syn III expression and DAT levels comparable to C57BL/6J mice, supporting that part of the cocaine-stimulated response of these mice is dependent on Syn III. MPH
effect can be positively fostered in the presence of α-syn and Syn III co-aggregates, in particular when the levels of these proteins are markedly elevated. MPH
stimulates α-syn/Syn III interaction in cells showing α-syn/Syn III co-aggregates likely by stabilizing α-syn in a conformation with low aggregation propensity.
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reported in Rao et al., (2010) showed the presence of 2KKW sequence
that can be identified as a potential source of interesting α-syn con-
formations suitable for such task. Indeed, by combining NMR and spin
labelling/electron paramagnetic resonance (EPR), Rao and co-workers
reported an ensemble of 34 α-syn structures exhibiting partially folded
conformations upon micelle binding (Rao et al., 2010). In one of these
conformations, by showing an N-terminal domain folded into a classical
α-helix secondary element in close proximity to the unfolded C-term-
inal domain and the central core adopting α-helix structure, α-syn re-
sults less prone to generate fibrillary aggregates (Kakish et al., 2015;
Rao et al., 2010). In the attempt to confirm the heuristic model for α-
syn in complex with MPH by Kakish and co-authors (Kakish et al.,
2015), we identified one α-syn conformation able to interact with MPH
within those reported by Rao and co-authors (Fig. 7A). Docking studies
of MPH in its d-threo configuration and this particular fl α-syn con-
formation confirmed that MPH interacts with the α-helix secondary
element-folded N-terminal domain of α-syn through the positively
charged Lys10 residue (Fig. 7B). Concomitantly, it plunges the posi-
tively charged nitrogen atom into a region of the proximal unfolded C-
terminal domain enriched in negatively charged residues and defined
by Asp119 and Asp121 residues, while the central core is stabilized into
an α-helix (Fig. 7B). This in silico model sounds also in agreement with
above described data showing that MPH is effective on SYN120 tg mice,
since Asp119 is conserved in the (1–120) α-syn construct (Fig. 7C), thus
supporting the reliability of the generated complexes.
These observations provide putative structural details underlying
the protective effect of MPH on α-syn/Syn III neuropathology. In par-
ticular, they support that MPH stabilizes α-syn into a conformation not
suitable to fibrillary aggregation, which rather displays improved ca-
pacity to establish a functional interaction with Syn III, that in turn
results in the observed Syn III-dependent locomotor activity.
Interestingly, this conformation is stabilized by micelle binding (Rao
et al., 2010), suggesting that lipids, or more probably synaptic vesicle
proximity, may promote its formation. Notably, α-syn aggregation can
cluster and disorganize synaptic vesicles (Faustini et al., 2018; Wang
et al., 2014). This evidence, when coupled to recent findings showing
that LB are constituted by a lipid crowded environment which contains
dispersed protein filaments (Shahmoradian et al., 2019), supports that
synaptic vesicles and organelles may be entrapped by α-syn/Syn III
fibrillary aggregates during LB formation. It may thus be feasible that
along with α-syn fibril deposition, different α-syn conformational var-
iants with diverse lipid binding affinity and function may be easily
generated. The Syn III-dependent MPH effect, likely mediated by an N-
terminal and central region α-helical α-syn conformation resulting from
lipid interaction, occurs only in aged SYN120 tg mice and seems to be
fully in line with a progressive lipid crowding model of LB. This not-
withstanding, due to the dynamic nature of α-syn, we cannot firmly
exclude that MPH could also stabilize different conformation/s with
respect of that analyzed in this study. It may be also feasible that spe-
cific post-translational modifications of α-syn may be relevant for MPH
action in SYN120 tg mice.
5. Conclusions
Collectively, our results support that Syn III and α-syn are both
involved in mediating the motor response to cocaine and MPH (Fig. 8).
Furthermore, they unveil that MPH effect can be positively fostered in
the presence of α-syn and Syn III co-aggregates, in particular when the
levels of these proteins are markedly elevated. Finally, we also found
that MPH stimulates α-syn/Syn III interaction in cells showing α-syn/
Syn III co-aggregates and provided a model supporting that this drug
stabilizes α-syn in a conformation with low aggregation propensity.
When seen in the light of clinical studies supporting the efficacy of MPH
in counteracting freezing of gait in advanced PD, our findings hint that
α-syn/Syn III pathological coaction could be the mediator of this effect.
This supports that drugs modulating α-syn/Syn III interplay may
constitute valid therapeutic options for treating this neurodegenerative
disorder. Not least, they hold significant implications also in the field of
ADHD.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nbd.2020.104789.
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